Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast.

Amplification of the Polycomb group transcriptional repressor Enhancer of Zeste 2 (EZH2) occurs in various malignancies including breast cancer, where its overexpression is associated with poor outcome. We found that EZH2 is up-regulated in ductal carcinoma in situ, atypical ductal hyperplasia, and even morphologically normal breast epithelial cells from women who have an increased risk of breast cancer. This review discusses how EZH2 may promote neoplastic conversion and it surveys the evidence suggesting that EZH2 may offer a clinical tool to help identify patients at risk for developing breast cancer before precursor lesions are histologically evident.

[1]  C. Meijer,et al.  Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. , 2004, Neoplasia.

[2]  Steve D. M. Brown,et al.  The murine polycomb-group genes Ezh1 and Ezh2 map close to Hox gene clusters on mouse Chromosomes 11 and 6 , 1999, Mammalian Genome.

[3]  M. Lohuizen,et al.  Cellular memory of transcriptional states by Polycomb-group proteins. , 1999, Seminars in cell & developmental biology.

[4]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[5]  P. V. van Diest,et al.  Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. , 2003, Neoplasia.

[6]  K. Helin,et al.  Regulation of cell proliferation by the E2F transcription factors. , 1998, Current opinion in genetics & development.

[7]  S. Merajver,et al.  Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. , 2006, Cancer research.

[8]  C. Meijer,et al.  Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. , 2000, The American journal of pathology.

[9]  J. Hess.  MLL: a histone methyltransferase disrupted in leukemia. , 2004, Trends in molecular medicine.

[10]  Stuart S Levine,et al.  Division of labor in polycomb group repression. , 2004, Trends in biochemical sciences.

[11]  R. Willemze,et al.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma , 2001, British journal of haematology.

[12]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Jenuwein,et al.  SET domain proteins modulate chromatin domains in eu- and heterochromatin , 1998, Cellular and Molecular Life Sciences CMLS.

[14]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Yi Zhang,et al.  Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. , 2005, Molecular cell.

[16]  C. Meijer,et al.  Increased Expression of the EZH 2 Polycomb Group Gene in BMI-1 – Positive Neoplastic Cells during Bronchial Carcinogenesis 1 , 2004 .

[17]  Stephen A Boorjian,et al.  Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder , 2005, Clinical Cancer Research.

[18]  J. Zeitlinger,et al.  Polycomb complexes repress developmental regulators in murine embryonic stem cells , 2006, Nature.

[19]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[20]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[21]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[22]  Ali Shilatifard,et al.  Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. , 2006, Annual review of biochemistry.

[23]  W. Alexander,et al.  Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice , 1991, Cell.

[24]  C. Nislow,et al.  Mammalian homologues of the Polycomb‐group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S.cerevisiae telomeres , 1997, The EMBO journal.

[25]  M. Stratton,et al.  The genetics of breast cancer susceptibility. , 1998, Annual review of genetics.

[26]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[27]  R. Strausberg,et al.  Mutation of GATA3 in human breast tumors , 2004, Oncogene.

[28]  S. Merajver,et al.  The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. , 2005, Neoplasia.

[29]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Johan Eide,et al.  Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.